1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-2128. doi: 10.1056/NEJMoa1504720
2. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016; 375: 323-334. doi: 10.1056/NEJMoa1515920
3. Fitchett D, Zinman B, Wanner C, et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: Results of the EMPA-REG OUTCOME trial. Eur Heart J. 2016; 37(19): 1526-1534. doi: 10.1093/eurheartj/ehv728
4. Bernstein LM, Blumberg B, Arkin MC. Osmotic diuretic treatment of refractory edema. Circulation. 1958; 17: 1013-1020. doi: 10.1161/01.CIR.17.6.1013
5. Aoki Y. Administration of sodium-glucose co-transporter 2 inhibitors could accelerate dehydration in poorly-controlled diabetic patients, proposing an option not to increase glucosuria but to decrease carbohydrate intake during hyperglycemia. Diabetes Res Open J. 2015;1: 72-74. doi: 10.17140/DROJ-1-111
6. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2 -receptor antagonist, for hyponatremia. N Engl J Med. 2006; 355: 2099-2112.
7. Aoki Y. Surprising results of the EMPA-REG OUTCOME study have brought a new insight into use of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes. Trop Med Surg. 2015; 3: 199. doi: 10.4172/2329-9088.1000199
8. Katsuno K, Fujimori Y, Takemura Y, et al. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007; 320: 323-330. doi: 10.1124/jpet.106.110296
9. Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014; 13: 148. doi: 10.1186/s12933-014-0148-1
10. Kasichayanula S, Liu X, Pe Benito M, et al. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol. 2013; 76: 432-444. doi: 10.1111/bcp.12056
11. Sarashina A, Ueki K, Sasaki T, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus. Clin Ther. 2014; 36: 1606-1615. doi: 10.1016/j.clinthera.2014.08.001
12. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodiumglucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32: 650-657. doi: 10.2337/dc08-1863
13. Devineni D, Curtin CR, Polidori D, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53: 601-610. doi: 10.1002/jcph.88
14. Kanada S, Koiwai K, Taniguchi A, Sarashina A, Seman L, Woerle HJ. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks’ treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Invest. 2013; 4: 613-617. doi: 10.1111/jdi.12110
15. Scholl-Buergi S, Santer R, Ehrich JHH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant. 2004; 19: 2394-2396. doi: 10.1093/ndt/gfh366
16. Calado J, Sznajer Y, Metzger D, et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant. 2008; 23: 3874- 3879. doi: 10.1093/ndt/gfn386
17. Matsuzaki M, Hori M, Izumi T, Fukunami M. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011; 1: S33-S45. doi: 10.1007/s10557-011-6304-x
18. Patra S, Kumar B, Harlalka KK, et al. Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: A prospective observational pilot study from a single center in South India. Heart Views. 2014; 15: 1-5. doi: 10.4103/1995-705X.132136
19. Chao EC, Henry RR. SGLT2 inhibition – anovel strategy for diabetes treatment. Nat Rev Drug Discov. 2010; 9: 551-559. doi: 10.1038/nrd3180
20. Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014; 129: 587-597. doi: 10.1161/CIRCULATIONAHA.113.005081
21. Shawkat H, Westwood M-M, Mortimer A. Mannitol: A review of its clinical uses. Contin Educ Anaesth Crit Care Pain. 2012; 1-4. doi: 10.1093/bjaceaccp/mkr063
22. Heerspink HJL, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2016; 28. doi: 10.1681/ASN.2016030278